For Healthcare Professionals

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients


About the study

A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve non-small cell lung cancer patients with EGFR mutation

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Histologically or cytologically confirmed non-small cell lung cancer.
  2. The ECOG score of performance status is 0-1.
  3. Locally advanced or recurrent metastatic NSCLC that has never received systemic treatment.
  4. According to RECIST1.1 criteria, there is at least 1 measurable lesion that has not been previously irradiated.
  5. Prior to enrollment, a central laboratory testing report has confirmed that the tumor has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy, accompanied with or not accompanied with other EGFR mutation, with the exception of exon 20 insertion.


Exclusion Criteria:

  1. Previously received systemic treatment for locally advanced or recurrent metastatic cancer.
  2. Primary T790M mutation-positive patient.
  3. Previous interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring hormonal therapy, or any clinically proven active interstitial lung disease.
  4. Known active infections such as hepatitis B, hepatitis C, and human immunodeficiency virus.
  5. Local radiation therapy is carried out within 1 week; more than 30% bone marrow radiation therapy or extensive radiation therapy is performed within 4 weeks.
  6. ≤ 4 weeks from major surgery or ≤ 2 weeks from minor surgery.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details



Age (in years)



Phase 3

Participants needed


Est. Completion Date

Feb 29, 2024

Treatment type



Beta Pharma, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.